Scientists have uncovered a potential blood‑based marker that could signal advanced chronic traumatic encephalopathy (CTE) in living individuals. The discovery, published in JAMA, stems from a study of 21 former football players who donated their brains for autopsy after death.
Study design and key findings
The research team, led by investigators from Boston University and Banner Health and including a specialist from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, measured levels of a tau protein fragment called eMTBR‑tau in the participants’ blood samples.
Autopsies confirmed CTE in 18 of the donors. Sixteen of those cases were classified as advanced disease, while two were early‑stage. The remaining three donors showed no signs of CTE. Those with advanced CTE exhibited significantly higher concentrations of eMTBR‑tau than the early‑stage group and the CTE‑negative donors.
Five of the advanced cases also displayed Alzheimer’s‑related brain changes, and these individuals had the highest tau fragment levels of all. Even after excluding these five donors, the difference between advanced CTE and the other groups remained statistically robust.
Comparison with prior research
A separate JAMA investigation examined blood plasma from 11 autopsy‑confirmed CTE cases within a larger cohort of 229 participants. That study similarly found the tau fragment helped distinguish advanced CTE from cognitively unimpaired controls, though results for the earliest disease stage were inconclusive.
Why the marker matters
CTE is a degenerative brain disease linked to repeated head impacts, commonly seen in contact‑sport athletes. Symptoms reported in affected individuals include memory loss, aggression, impulse‑control difficulties, mood swings, and, in some cases, suicidal thoughts. Until now, definitive diagnosis required post‑mortem brain examination.
“If we can validate our findings and this holds up, it’s gonna really change the landscape of clinical research and clinical care,” said Michael Alosco, co‑senior author of the football‑player study and co‑director of clinical research at Boston University’s CTE Center, in an interview with WBUR.
Potential impact on treatment and research
A reliable blood test could enable doctors to identify patients who might benefit from emerging therapeutic trials, accelerating the development of interventions aimed at slowing or halting disease progression. It would also allow families and clinicians to make more informed decisions about health management and lifestyle adjustments.
The researchers caution that larger, multi‑center studies are needed to confirm the marker’s accuracy, determine its ability to differentiate CTE from other neurodegenerative conditions, and establish standardized testing protocols.
Broader context
Estimates suggest that at least one in four former NFL players who died between 2016 and 2021 had CTE, underscoring the urgency of early‑detection tools. In July, Boston University researchers diagnosed former Dallas Cowboys defensive end Marshawn Kneeland with stage 1 CTE after his death; Kneeland had reportedly expressed suicidal thoughts before his apparent self‑inflicted gunshot wound.
While the new blood marker is not yet ready for clinical use, the findings represent a significant step toward a non‑invasive diagnostic option for a disease that has long eluded living‑patient detection.
Original reporting: WBAP News/Talk (Dallas-Fort Worth) — read the source article.